EBUS-TBNA of a Left Lower Paratracheal Node (Level 4 L) in a Patient with a Left Upper Lobe Lung Mass and Suspected Lung Cancer

Published on 23/05/2015 by admin

Last modified 22/04/2025

Print this page

This article have been viewed 1246 times

Chapter 17 EBUS-TBNA of a Left Lower Paratracheal Node (Level 4 L) in a Patient with a Left Upper Lobe Lung Mass and Suspected Lung Cancer

This chapter emphasizes the following elements of the Four Box Approach: operator and team experience and expertise, and techniques and instrumentation.

Case Description

A 72-year-old man with 40–pack-year history of smoking presented with chronic cough. Computed tomography of the chest showed a 2.8 × 1.7 cm left upper lobe mass and a 1.57 cm short diameter left lower paratracheal lymph node (Figure 17-1). The patient was referred for diagnosis and staging. He had a history of COPD (post bronchodilator FEV₁ was 58% predicted) and stable angina pectoris treated medically by his cardiologist. On chest auscultation, decreased air entry bilaterally and prolonged exhalation were noted. He was independent in his daily activities but performed them with effort. Karnofsky performance status was 80. Resting and two-dimensional dobutamine stress echocardiography was normal. He lived with his wife at home, desired a prompt diagnosis, and was willing to consider all available treatment options.

Figure 17-1 A, Axial computed tomography (CT) view reveals the left upper lobe mass and the 1.7 cm left paratracheal lymph node (station 4 L) to the left of the left lateral border of the trachea. B, Coronal CT view reveals the relationship between the left paratracheal node, the pulmonary artery, and the aortic arch.

Discussion Points

1. Describe the diagnostic yield of EBUS-TBNA versus conventional TBNA and EUS-FNA at station 4 L.

2. Describe how the coronal view of a computed tomography scan can be used to help plan EBUS-TBNA.

3. Describe endobronchial sonographic findings, including adjacent vascular structures at and around lymph node station 4 L.

Case Resolution

Initial Evaluations

Physical Examination, Complementary Tests, and Functional Status Assessment

This patient had decreased air entry bilaterally and prolonged exhalation, consistent with his obstructive ventilatory impairment detected on spirometry. He had grade II functional status based on the World Health Organization scale, specifically, mild limitation of physical activity was noted; no discomfort was reported at rest, but normal physical activity caused increased symptoms.¹ Other measurement instruments that can be used to accurately assess impaired health, perceived well-being, dyspnea, and quality of life in patients with chronic obstructive pulmonary disease (COPD) are St. George’s Respiratory Questionnaire, the Borg Baseline Dyspnea Index (BDI), and the modified Medical Research Council (MRC) Dyspnea Scales.²

Results from prospective studies of COPD patients with a mean age of 65 years and a mean value of post bronchodilator forced expiratory volume in 1 second (FEV₁) of 44% of the predicted value show that the all-cause mortality rate is 12% to 16% at 3 years.³ Our patient, however, additionally had a lung nodule, ipsilateral mediastinal lymphadenopathy, and a positive smoking history. These findings are highly suspicious for primary lung carcinoma. If non–small cell lung cancer (NSCLC) were diagnosed, the primary tumor size would be staged as T1; in conjunction with positive N2 nodal staging (ipsilateral mediastinal lymphadenopathy), this patient would be staged clinically as having IIIA disease with an estimated 5 year survival of 19% and a median survival of 14 months despite treatment.⁴ Because his risk of dying from cancer far outweighs that of dying from COPD, prompt diagnosis, staging, and treatment of his lung cancer are warranted.

Survival estimates are critical factors in patient and physician decision making in all phases of cancer diagnosis and treatment. These estimates are not perfect and of course may not apply to the particular “individual” faced with a cancer diagnosis. One measure that has been used to predict survival and consequently has been used as an entry criterion for oncology clinical trials is performance status. The Karnofsky Performance Scale, for example, is a commonly used general measure of functional impairment that allows comparison of the effectiveness of various therapies and prognosis considerations in individual patients: The lower the score, the worse the chance of survival.⁵

Comorbidities

This patient had COPD with FEV₁ of 58% predicted (moderate; Gold Initiative on Obstructive Lung Disease [GOLD] stage II). He was taking tiotropium 18 mcg/day and albuterol by metered dose inhaler (MDI) as needed. He had stable angina pectoris managed medically with nitrates and calcium channel blockers. The patient had no signs or symptoms of other illnesses. Careful examination and review of systems are warranted because COPD is linked to many comorbid conditions such as hypertension, coronary heart disease, stroke, obstructive sleep apnea, psychiatric illness (e.g., depression, anxiety), and cognitive decline, which could preclude or complicate interventions provided under general anesthesia.^6,⁷

Support System

Our patient was married and lived with his wife, who was very supportive. Cancer, as suspected in this patient, is often considered a “family matter” with significant psychological and emotional impact on family members.⁸ Because significant others are often involved in caregiving to a considerable extent during a patient’s illness, involvement of family members in discussions about diagnosis and prognosis is warranted. Additionally, health care providers should be concerned about the caregiver’s health because several investigators have found that caregiving, although it is not always judged to be a negative experience, can contribute to mental and physical ill health and can have a negative impact on social functioning.⁹

Patient Preferences and Expectations

This patient had clearly expressed a desire for treatment. He was prepared to consider all available diagnostic options, including conventional transbronchial needle aspiration (TBNA), endobronchial ultrasound (EBUS)-guided TBNA, endoscopic ultrasound (EUS)-guided fine-needle aspiration (FNA), computed tomography (CT)-guided biopsy, mediastinoscopy, or video-assisted thoracic surgery (VATS).

Although increasing emphasis is now placed on patient empowerment, results of studies show that many patients do not wish to be involved in decisions about their own care. Patient preferences regarding involvement in decision making vary with age, socioeconomic status, and illness experience, as well as the gravity of the decision. Evidence suggests that even if patients wish to be informed about their illness and treatment alternatives, they might not wish to be actively involved in making the treatment decision.¹⁰ Therefore the distinction between providing information, evaluating the information given, and taking responsibility for deciding on treatment may be important. In our case, the patient explicitly asked that all information and alternatives be discussed with both him and his wife, so they could make medical decisions together.

Procedural Strategies

Indications

Tissue diagnosis and sampling of station 4 L (left lower paratracheal node) for staging purposes were warranted because mediastinal lymph node involvement is found in approximately 26% of patients with newly diagnosed lung cancer.¹¹ Sampling of the 4 L lymph node station is important because the presence of mediastinal lymph node metastasis remains one of the most adverse prognostic factors in NSCLC. This tumor can be subclassified as IIIA3 with significant implications for additional management decisions. This is the largest subgroup of IIIA NSCLC patients and consists of patients with clinical ipsilateral lymph node invasion demonstrated by minimally invasive techniques or noninvasive imaging. Patients are often considered resectable or marginally resectable, depending on the number and the location of the lymph nodes involved.¹² However, the American College of Chest Physicians (ACCP) states that in NSCLC patients with stage IIIA-N2 disease identified preoperatively, induction therapy followed by surgery is not recommended, except as part of a clinical trial. Furthermore, although the use of any induction chemotherapy followed by surgery in stage IIIA lung cancer appears feasible, published data do not support this treatment as the standard of care in the community.¹³ In fact, concomitant chemoradiation is increasingly becoming the standard of care in selected patients in clinical stage IIIA3 with a good risk profile, that is, low comorbidity, good performance and pulmonary function, and adequately staged disease.¹²

Although imaging studies are helpful for identifying lung parenchyma and mediastinal abnormalities, they do not provide a tissue diagnosis. Flexible bronchoscopy would allow complete airway inspection to ascertain the absence of endobronchial lesions, to potentially obtain samples from the lung mass itself, and to sample the mediastinal lymph node at the same setting. This could be done with the use of conventional transbronchial needle aspiration; however, the use of EBUS-TBNA significantly increases diagnostic yield (96% vs. 41%) at the level 4 L region compared with conventional sampling techniques.^14,¹⁵ By sampling station 4 L, both diagnosis and staging can be accomplished during a single procedure. Complete sonographic mediastinal lymph node assessment is warranted, however, because the tumor may be upstaged to N3 (stage IIIB), in case EBUS identifies contralateral lymph nodes and aspirates are positive for malignancy.¹⁶ One study showed that compared with radiologic staging, EBUS-TBNA downstaged 18 of 113 (15.9%) and upstaged 11 of 113 (9.7%) patients.¹⁷ Therefore ultrasound examination is done in a stepwise fashion, usually beginning at the highest-level node in relation to the lung mass in staging procedures: Contralateral lymph nodes, when identified, are sampled first and are immediately stained and read by an on-site pathologist. If no malignant cells are seen, subcarinal or ipsilateral lymph nodes are sampled. All aspirates are stained immediately for rapid on-site interpretation; aspirates are obtained until a preliminary cytologic diagnosis of malignancy is given, or until the cytologist determines that an adequate quantity of representative tissue has been obtained (usually four aspirates per lesion).¹⁸ For this patient, if complete EBUS mediastinal and hilar evaluation reveals no contralateral nodes, the CT-documented 4 L node should be sampled.

Contraindications

No absolute contraindications to EBUS-TBNA were noted. This procedure is often performed under general anesthesia, which in our patient could predispose to myocardial ischemia as the result of volume shifts and increased myocardial oxygen demand from elevations in heart rate and blood pressure. Patients with major cardiac predictors for anesthesia risk such as unstable coronary syndrome, decompensated heart failure, significant arrhythmia, and severe valvular disease warrant intensive management, which may lead to delay in cancellation of an operative procedure. Other clinical predictors that require careful assessment include a history of ischemic heart disease (as seen in our patient), diabetes mellitus, compensated heart failure, and renal insufficiency. It is noteworthy that diagnostic endoscopic procedures such as bronchoscopy are considered low risk with a reported rate of cardiac death or nonfatal myocardial infarction of less than 1%; therefore preoperative cardiac testing usually is not necessary.¹⁹ The negative stress test performed several weeks earlier was reassuring because of its high negative predictive value (90% to 100%) for postoperative cardiac complications.²⁰

Expected Results

We usually perform EBUS-TBNA with a large endotracheal tube (8.5 or 9 mm) with the patient under general anesthesia. The EBUS scope would be introduced through the tube once the bite block is secured in place around the tube. Some practitioners prefer using a laryngeal mask airway or inserting the EBUS bronchoscope through the mouth with the use of a bite block under moderate or deep sedation. Complete airway examination would be performed and attention would be paid to both contralateral and ipsilateral mediastinal lymph node stations with EBUS.

In one small study, the diagnostic rate of EBUS-TBNA for station 4 L was equal to that of conventional TBNA (72% vs. 71%), but lymphocytes (indicative of an adequate sample) were more often present on EBUS-TBNA specimens (82% vs. 71%).²¹ Several larger studies, however, have shown high diagnostic yields of 88% to 96% with EBUS for station 4 L.^14,^22,²³

Team Experience

Although the yield of EBUS-TBNA has generally been reported to be as low as 70% for all lymph node stations,²⁴ it has become standard practice in most institutions that can offer it. An experienced team of doctors and nurses familiar with the techniques and the equipment is necessary. On-site cytology is preferred to provide immediate diagnosis, or at the least to know whether representative samples are being obtained. However, many bronchoscopists do not use rapid on-site cytologic examination because of cost, logistics, and organizational issues, stating instead that because the operator visualizes nodal sampling, immediate cytology is not necessary. On the other hand, having an immediate result of malignancy might increase the yield of the procedure and prevent the need for additional specimens from other nodal sites, thus potentially decreasing the time required for the procedure and potentially the associated complications. This issue continues to be debated within professional circles. A systematic review and meta-analysis showed that on-site evaluation of cytologic specimens had the highest pooled sensitivity at 0.97 (95% confidence interval [CI], 0.94 to 0.99); however, because of potential heterogeneity, when pooled sensitivity was compared with that of other subgroups, no statistical significance was found (P > .05).²⁵ In addition, for pathologists, this is a relatively time-consuming procedure, with a mean of 22 minutes spent on an average of three passes performed, with six slides prepared per lymph node site.²⁶

Risk-Benefit Analysis

EBUS-TBNA has a high yield and is a safe same-day procedure.²⁵ One serious complication (pneumothorax requiring chest tube drainage) was reported in a meta-analysis of 1299 patients. Cough and the presence of blood at the needle puncture site are infrequent.²⁷ Even when performed by a single individual using moderate sedation in a single center, patient satisfaction was high, and no complications occurred that might have compromised diagnostic yield.²⁸

Anecdotal reports show evidence of clinically significant bacteremia and polymicrobial pericarditis with tamponade physiology after EBUS-TBNA; these complications were considered to be caused by direct inoculation of oropharyngeal flora into mediastinal tissue during full EBUS-TBNA with needle extension to 3.6 cm.²⁹ Some investigators have suggested that contamination of the TBNA needle by oropharyngeal flora is common and may predispose patients to clinically significant infection, although this occurs rarely.³⁰ Results from a prospective study document the presence of bacteremia, confirmed by blood culture within 60 seconds of EBUS-TBNA, in 7% (3/43) of patients, compared with 0% to 6% rates following routine bronchoscopy, but no clinically significant infections have been described (none of the three bacteremic patients had clinical features suggestive of infection within 1 week of EBUS-TBNA). Bacteremia, universally caused by oropharyngeal commensal organisms, is considered by some investigators to be the likely result of insertion of the bronchoscope itself. Investigators postulate that as the bronchoscope traverses the naso-oropharyngeal region, the working channel becomes contaminated. As a result, when the transbronchial needle passes through the working channel, it becomes contaminated and can potentially inoculate the sampled tissue. Although the needle designed for the EBUS scope has an outer sheath, which could minimize sample contamination, this sheath is still passed through the working channel. When the needle is advanced at the site of interest, it is passed through the distal end of this sheath and could become contaminated. In addition, needle penetration depth may contribute to contamination and infection, especially if the tip of the fully extended needle is out of the scanning plane, and the pericardium or vessels can be violated but not visualized.²⁹

Diagnostic Alternatives

Various alternatives are available, each with its advantages and disadvantages. It is ethical to share a description of these alternatives with the patient and his spouse:

1. CT-guided percutaneous needle aspiration of the left upper lobe nodule could be performed because the diagnostic rate (91%) is high. This would not provide information on staging, is associated with increased risk for pneumothorax (5% to 60%),³¹ and provides no information regarding airway lesions and potential resectability. If cancer were diagnosed, mediastinal sampling would still be warranted for staging purposes.

2. EUS-FNA (endoscopic ultrasound-guided fine-needle aspiration) could be performed because the 4 L lymph node station is accessible via the esophagus. Overall reported sensitivity is 81% to 97%, and specificity is 83% to 100%.³² For station 4 L in particular, EUS-FNA has a diagnostic yield similar to EBUS-TBNA.²³ Some might argue that bronchoscopy would still need to be performed to identify possible airway abnormalities. Rates of bacteremia following upper EUS are similar whether or not FNA is performed and are equal to those seen in routine gastroscopy (6%).³³

3. Mediastinoscopy is still considered the gold standard and may be recommended if endoscopic sampling of station 4 L is negative for malignancy and is otherwise nondiagnostic.¹⁴ This invasive procedure is performed in the operating room with the patient under general anesthesia. It has associated morbidity and mortality of 2% and 0.08%, respectively.³⁴ Mediastinoscopy has a specificity of 100% and offers good access to lymph node stations 2, 4, and 7, but access to posterior and inferior mediastinal nodes is limited, which explains its overall sensitivity of 80% to 90%.³¹

4. Video-assisted thoracic surgery (VATS) is another invasive alternative but provides access to ipsilateral nodes only and has 75% sensitivity overall.³⁵ Its benefits include access to inferior mediastinal nodes and definitive lobar resection at the same time if nodes are negative.

Cost-Effectiveness

In two separate decision-analysis models, EUS-FNA + EBUS-TBNA and conventional TBNA + EBUS-FNA were more cost-effective approaches than mediastinoscopy for staging patients with NSCLC and abnormal mediastinal lymph nodes on noninvasive imaging.^36,³⁷ The strategy of adding EUS-FNA to a conventional lung cancer staging approach (mediastinoscopy and thoracotomy) reduced costs by 40% per patient.³⁸ The two procedures (EUS-FNA and EBUS-TBNA) can be performed with the use of a dedicated linear EBUS bronchoscope in one setting and by one operator. Procedures are complementary and their combined use provides better diagnostic accuracy than is attained with either procedure alone.³⁹ This approach may reduce costs and enhance efficiency if one person can perform the combined procedure; simultaneously scheduling two skilled endoscopists with different subspecialties is often difficult.

EBUS-TBNA may actually increase health care costs if done in low-volume centers by inexperienced operators.⁴⁰ In fact, start-up costs are significant because of the need for training (participation in national and international hands-on workshops), equipment costs, and the risk that costly repairs will be needed in cases of instrument damage.⁴¹

Informed Consent

After they had been advised of all of the diagnostic alternatives, the patient and his wife elected to proceed with EBUS-TBNA under general anesthesia. No barriers to learning were identified. They were informed of potential failure to obtain a definitive diagnosis despite successful lymph node visualization and sampling. Feedback communication techniques were used to confirm patient understanding of his disease. Both the patient and his spouse were able to accurately describe the proposed procedure, alternatives, and potential complications.

Techniques and Results

Anesthesia and Perioperative Care

EBUS-TBNA can be performed with the patient under conscious (moderate) sedation or under general anesthesia with the use of a laryngeal mask airway or endotracheal tubes:

1. Conscious (moderate) sedation: In a single center, it was shown that despite frequent cough (70% of patients), patient satisfaction was high and diagnostic yield remained 90%.²⁸ Moderate sedation offers the advantage of performing the procedure in the bronchoscopy suite and results in better cost savings/safety ratios when compared with general anesthesia.⁴² Cough and respiratory movements, however, may impair coupling of the transducer with the airway wall and may result in significant artifacts and suboptimal ultrasound imaging. Sampling of smaller nodes may be technically more difficult than that done with the patient under general anesthesia.

2. General anesthesia with laryngeal mask airway (LMA) is preferred in many institutions. It is possible to establish a secure airway and maintain oxygenation using the LMA during bronchoscopy without diminishing the chances for a successful procedure.²⁴ At least a No. 4 or a No. 4.5 LMA should be used to allow straightforward manipulation of the scope inside the airway.⁴³ LMAs of this size allow passage of endotracheal tubes (ETTs) if necessary. Anesthesia given by LMA allows visualization of higher mediastinal structures and lymph nodes at stations 1 and 2 compared with ETTs for obvious reasons: After intubation, the distal extremity of the ETT is at least 3 cm below the vocal cords because the distance between the tip of the tube and the cuff of the tube is usually 1 cm, and the cuff length is approximately 2 cm. Were the tube higher within the trachea, the cuff would abut or sit within the larynx. If an ETT is used, it will have to be mobilized proximally to allow examination of stations 1 and 2. General anesthesia and the LMA are used in the bronchoscopy suite in some centers and in the operating room in others, depending on logistics, personnel, and institutional policies. Patients should be selected carefully because use of an LMA may not be appropriate in severely obese patients or in patients with severe untreated gastroesophageal reflux (GERD) because of the known reduction in barrier pressure at the lower esophageal sphincter and increased risk for aspiration of gastric contents.⁴⁴

3. General anesthesia with endotracheal tube (ETT): A No. 8.5 ETT for female patients and a No. 9 ETT for male patients should be used to allow for proper ventilation and to potentially prevent elevated peak airway pressures and development of auto–positive end-expiratory pressure (PEEP) during the procedure. These tubes provide at least a 2 mm difference between the scope diameter and that of the ETT because the outer diameter of the EBUS-TBNA scope is 6.2 mm. This bronchoscope/ETT ratio may prevent critical alterations in ventilatory parameters.⁴⁵ The procedure is usually performed in the operating room. Because the EBUS scope is directed more centrally in the airway through the ETT, coupling of the transducer and the wall may be impaired, and biopsy may be more difficult to perform than with LMA or moderate sedation techniques.⁴³

During the time-out process, the need for perioperative antibiotics is readdressed by the anesthesia team. Current evidence suggests that given a bacteremia rate comparable with that of routine flexible bronchoscopy, recommendations for the use of prophylactic antibiotics for the prevention of infective endocarditis in patients undergoing EBUS-TBNA should not differ from those for routine bronchoscopy. The latest guidelines recommend antibiotic prophylaxis for bronchoscopic procedures only in patients with cardiac conditions such as congenital heart disease, prosthetic heart valves, or previous history of infectious endocarditis.⁴⁶ Our patient had no such conditions.

Instrumentation

The EBUS bronchoscopes used for diagnosing and staging mediastinal lymph nodes in lung cancer are dedicated real-time EBUS-TBNA scopes.^47,⁴⁸ These scopes are similar in design, but their physical characteristics may be slightly different (Table 17-1).

Table 17-1 Specifications for Commercially Available Endobronchial Ultrasound Bronchoscopes

The bronchoscope used in our case had a curved array 7.5 MHz ultrasound transducer incorporated into its distal end (BF-UC 160F, Olympus Optical Co., Ltd., Tokyo, Japan) (Figure 17-2, A). Resolution is low, but optimal depth of penetration is approximately 5 cm, which allows clear visualization of mediastinal structures surrounding the airways. The ultrasound processor (Figure 17-2, B) (Olympus Endo Echo EU C2000) allows for adjustable gain and depth to improve image quality and has Doppler capabilities that help to distinguish lymph nodes from mediastinal vascular structures (see video on ExpertConsult.com) (Video IV.17.1). The dedicated 22 gauge acrogenic needle has a stylet and a lockable sheath. Precise needle projection is up to 4 cm (Figure 17-2, C and D). The stylet allows the operator to expel bronchial cells inside the node that might otherwise contaminate the specimen during the aspiration process (see video on ExpertConsult.com) (Video IV.17.2).

Figure 17-2 Endobronchial ultrasound equipment. A, Endobronchial ultrasound (EBUS) scope (BF-UC 160F) with the curved array 7.5 MHz ultrasound transducer incorporated into the distal end of the bronchoscope. B, The ultrasound processor unit (EU C 2000) allows for adjustable gain and depth to improve image quality and has Doppler capabilities. C, The 22 gauge needle system is being locked to the bronchoscope. D, Endoscopic view showing the water-inflated balloon (arrow) against the airway wall and the needle extended out of its sheath, penetrating the airway wall.

Anatomic Dangers and Other Risks

The pulmonary artery and the aortic arch surround station 4 L (see Figure 17-1). The risk of puncturing these and other major vessels may be reduced by using real-time B-mode and Doppler mode imaging. Minor bleeding at the puncture site has been reported but no cases of major bleeding have been described.⁴⁹ Pneumothorax and pericarditis have occurred after conventional TBNA but are very rarely reported in the EBUS-TBNA literature.^25,²⁹

Results and Procedure-Related Complications

EBUS-TBNA was performed with the patient under general anesthesia using a 9.0 ETT. Bronchoscopic inspection showed normal airway mucosa without evidence of endobronchial disease. A total of three aspirates were performed from station 4 L. With the use of rapid on-site cytology examination, a diagnosis of non–small cell carcinoma (likely adenocarcinoma) was made. No procedure-related complications were reported.

When EBUS-TBNA is performed, a cytology specimen can be considered adequate or representative if frankly malignant cells are present, as in our case. Lymphocytes, lymphoid tissue, and clusters of anthracotic pigment-laden macrophages are also signs of a representative (being within the lymph node) sample.⁵⁰ The specimen is considered inadequate or nonrepresentative if no cellular components are present, and if the specimen contains scant lymphocytes (defined as <40 per high-power field [HPF]) and blood only, cartilage, or bronchial epithelial cells only.⁵¹ A quantitative cutoff value of at least 30% cellularity composed of lymphocytes has been arbitrarily proposed by some experts.⁵² Higher yields may be obtained by taking aspirates from the periphery of the node. The case lasted 30 minutes from induction to extubation. Extubation was uneventful, and the patient was transferred to the postanesthesia care unit for 2 hour observation, during which no complications were noted. He was discharged home the same day.

We chose to use rapid on-site examination (ROSE) because of its availability at our institution. The procedure was stopped once the pathologist determined specimen adequacy. A firm and unquestionable diagnosis at the time of EBUS-TBNA was not required. Literature shows that if ROSE is not utilized, the greatest diagnostic yield is obtained by performing three aspirates per lymph node station (reported sensitivity of 95% and specificity of 100%).⁵¹ Two aspirations per lymph node station seem to be acceptable if at least one tissue core specimen is obtained. If the operator believes that targeting is inadequate or insufficient, additional aspirates should probably be obtained, regardless of the number of passes.

Long-Term Management

Outcome Assessment

The patient was discussed in a multidisciplinary chest conference attended by chest radiologists, along with representatives from cardiothoracic surgery, oncology, and radiation oncology. He was potentially eligible to be enrolled in a clinical trial of neoadjuvant treatment of stage IIIA adenocarcinoma of the lung.¹³ Five-year survival for all treated patients with clinical stage IIIA non–small cell lung cancer is 19%.⁴ Patients with stage IIIA disease usually are stratified radiographically into those with nonbulky (stage IIIA3) or bulky (stage IIIA4) mediastinal lymph node disease.¹² The definition of bulky mediastinal lymphadenopathy varies in the literature, but it is reasonably defined as lymph nodes larger than 2 cm in short-axis diameter, as measured by CT, groupings of multiple smaller lymph nodes, or involvement of more than two lymph node stations.¹³ The distinction between nonbulky and bulky stage IIIA and IIIB disease is useful primarily in selecting patients for surgical resection after neoadjuvant therapy. Our patient’s mediastinal lymphadenopathy included only one station, and the node was smaller than 2 cm; the disease was therefore determined to be stage IIIA3 (see Figure 17-1).

Discussion Points

1. Describe the diagnostic yield of EBUS-TBNA versus conventional TBNA and EUS-FNA at station 4 L.

According to a study that directly evaluated the yield of EBUS-TBNA versus conventional TBNA for separate lymph node stations, the diagnostic yield of EBUS-TBNA was similar to that of conventional TBNA (72% vs. 71%) at station 4 L, but lymphocyte-positive aspirates were retrieved more commonly with EBUS-TBNA (82% vs. 71%). In a more recent paper with a large number of patients, the yield of EBUS-TBNA for diagnosing station 4 L was as high as 96% in expert hands ¹⁴ and was much higher than the yield of 41% reported with conventional TBNA for this lymph node station.¹⁵ For station 4 L, EUS-FNA has a diagnostic yield similar to that of EBUS-TBNA.²³

2. Describe how the coronal view of a computed tomography scan can be used to help plan EBUS-TBNA.

According to the International Association for the Study of Lung Cancer (IASLC) lymph node map,⁵⁶ station 4 L includes nodes to the left of the left lateral border of the trachea, medial to the ligamentum arteriosum. The upper border is the upper margin of the aortic arch, and the lower border is the upper rim of the left main pulmonary artery (see Figure 17-1). Both axial and coronal CT views are useful to define station 4 L and identify adjacent vascular structures. The coronal CT view, however, is more useful for correlation with the EBUS image, as is explained later.⁵⁷

To visualize the left paratracheal node (4 L), the operator turns the bronchoscope laterally to the 9 o’clock position and scans the area of lymph node station 4 L (Figure 17-3, A). Therefore the scanning plane for the EBUS scope is the same as that for the coronal CT view (Figure 17-3, B). However, although the coronal CT view is projected as if the scope is vertical, the EBUS image is projected as if the scope is horizontal (Figure 17-3, C). Thus to understand the use of the coronal CT view, one must understand the reference points on the EBUS image (see Figure 17-3, C). The green dot on the monitor represents the point where the needle exits the scope and corresponds to the superior (cephalad) aspect of the body. This dot is by default toward the 1 o’clock position on the screen (see Figure 17-3, C). Reorientation of the coronal CT image is necessary to bring the scope to a horizontal position and to bring the green dot cephalad (toward the 1 o’clock position on the screen) to match the EBUS image. For practical purposes, one can print out or save the coronal CT image showing station 4 L as a separate picture. This picture is then rotated clockwise to “horizontalize” the scope and bring the green dot cephalad toward the 1 o’clock position (Figure 17-4).

3. Describe endobronchial sonographic findings, including adjacent vascular structures at and around lymph node station 4 L.

Figure 17-3 A, Bronchoscopic view shows the endobronchial ultrasound (EBUS) scope with the transducer oriented toward the left lateral wall of the trachea at the 9 o’clock position when the patient is bronchoscoped from the head; the scanning plane is parallel to the insertion direction and is oriented toward the left side of the trachea. B, Close view coronal computed tomography (CT) image reveals station 4 L (lymph node [LN]), the aortic arch (cephalad), and the pulmonary artery (caudal). Schematic representation of the EBUS scope inside the trachea and the scanning range of 50 degrees. C, Bronchoscopic ultrasound image is projected as if the EBUS scope were horizontal. The green dot (arrow) is oriented toward the cephalad portion of the body.

Figure 17-4 A, Coronal computed tomography (CT) image adjustments are made to bring the green dot cephalad, as in the endobronchial ultrasound (EBUS) image. B, Coronal CT image is projected as if the EBUS scope were horizontal. The aortic arch is cephalad, and the pulmonary artery is caudal. C, The EBUS image, projected by default as if the scope were horizontal, shows the same structures that are seen on the adjusted coronal CT image.

The coronal CT image and the EBUS image correlate and show the same structures in the same locations, as well as the characteristic EBUS image at station 4 L (see Figure 17-4).

Expert Commentary

provided by Kenneth Chang, MD

The authors have presented a thorough and comprehensive review of the diagnosis, staging, and therapeutic strategies for this illustrative case. An alternative approach would have been to perform EUS-FNA at the same time (or before) EBUS. The instrumentation, technique, and expected results of EUS-FNA at station 4 L will be discussed.

Instrumentation

With EUS, two different scopes can be used alone or in combination. Radial instruments utilize a mechanical or an electronic rotating transducer that creates a 360 degree ultrasonographic image that is perpendicular to the axis plane of the echoendoscope. In the esophagus, this gives a spatial orientation of the image similar to that obtained with CT of the chest. Current radial echoendoscopes have the ability to switch frequencies from 5 MHz up to 10 MHz to optimize imaging. The main limitation of the radial echoendoscope is its inability to safely perform FNA, because the needle path cannot be tracked accurately.

On the other hand, linear-array echoendoscopes permit the performance of FNA. The ultrasound transducer generates a 100 to 180 degree image that is parallel to the shaft of the echoendoscope, allowing full visualization of a needle that is passed through the working channel of the device. The anatomic orientation is at an angle of 90 degrees to the radial anatomy. Linear echoendoscopes also have a frequency range of 5 to 10 MHz. The needle for FNA can be tracked in its entirety from exiting the biopsy channel to entering and aspirating the target lesion. Linear echoendoscopes also provide the ability for color flow and Doppler imaging to choose an FNA needle path that avoids vascular structures by combining simultaneous real-time ultrasonography with Doppler ability. For mediastinal nodal staging, we prefer to start with the radial echoendoscope, which provides 360 degree imaging, followed by the linear echoendoscope for performing FNA.

Technique

A vast majority of cases are performed with the patient under moderate sedation, usually with a combination of meperidine and midazolam. General anesthesia is reserved for those patients with sleep apnea, previously failed moderate sedation, severe comorbidities, or age over 80. The echoendoscope is advanced by direct visualization through the mouth into the proximal esophagus. For acoustic coupling, the water balloon surrounding the transducer can be inflated. Water balloon imaging is always used to couple the entire esophageal lumen when performing radial EUS. Unlike EBUS, the esophageal lumen can be completely occluded during sustained imaging. For linear EUS, minimal balloon coupling may be used to improve surface contact. Staging of lung cancer usually begins by imaging the liver for possible metastasis. The right lobe is imaged through the duodenum, and the left lobe is imaged through the gastric fundus. In addition, the left adrenal gland is imaged, because lung cancer not infrequently can metastasize to the adrenal gland.⁵⁸ The right adrenal is more difficult to image through the duodenum, in which case the scope is positioned in the gastric cardia, where the aorta is positioned at 6 o’clock (similar to CT of chest) and is followed proximally from the level of the celiac artery. The hepatic veins merging into the inferior vena cava can be imaged at this level as well. The next structure that is visualized during scope withdrawal is the base of the heart, including the right atrium. Next, the left atrium is most prominent when a four-chambered view of the heart and the descending aorta is obtained. Slightly more proximal, the pulmonary veins coming into the left atrium can be seen, along with the aortic outflow tract, the azygos vein, and the superior vena cava (SVC). Further withdrawal brings to view the subcarinal region, with visualization of the right and left mainstem bronchi. Next is the region of the descending aorta and pulmonary arteries (the right pulmonary artery is prominently visualized as it comes under the ascending aorta and SVC). More proximally, the aortic arch comes into view, followed by the right and left carotid arteries and internal jugular veins. Thus all lymph node stations can be assessed with the exception of 10 L and 10R (Figure 17-5).

Figure 17-5 Nodal stations from the perspective of the esophagus.

Performing FNA

The most commonly used FNA needle size has changed in many institutions, including ours, from the 22 gauge to the 25 gauge needle. The technique involves having the lesion to be biopsied placed in the center or just to the left of center in the imaging field.⁵⁹ If concern arises regarding surrounding vascular structures, Doppler imaging can be used to better define potential vessels. The needle is then advanced through the biopsy channel and can be seen exiting the biopsy channel into the lymph node under real-time ultrasonography. Although suction with a 10 mL syringe has been used for two decades, advancements have led to the use of no suction or the “stylet pull-back” technique while quick to-and-fro movements of the needle are made within the node. Studies have shown that suction creates a bloody specimen, especially when FNA is performed in lymph nodes. The needle is removed and is immediately placed onto a glass slide and is processed by a cytopathology technician within the unit. We now place the first and last drops on the slide and the remainder of the material into the formalin bottle for cell block. While the first slide is being processed and reviewed, we may take a second pass while waiting for the preliminary cytologic interpretation from the preceding pass. This continues until cytologic adequacy for interpretation is attained. Typically, only one or two passes are required to yield an adequate specimen.

The specific technique for assessing and performing FNA of station 4 L lymph nodes is as follows. The linear echoendoscope is advanced into the distal esophagus. With the descending aorta in the longitudinal position, the scope is withdrawn while the aorta is kept in view at the 6 o’clock position (Figure 17-6) until the aortic arch is identified. At this point, rotation of the scope will allow visualization of the aortopulmonary window and left lower paratracheal (4 L) nodes (Figure 17-7).